JACC. Advances · 2025
Raising the Alarm: Underdiagnosis of Cardiac Sarcoidosis in Young Patients With Unexplained Heart Block.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Goldar Ghazaleh, Sifuentes Aaron A, Gokul Kaushik, ElBakkush Usamah M, Mhanna Mohammed, Farjo Peter, Dominic Paari
Аннотация
BACKGROUND: Cardiac abnormalities are often the first or only sign of sarcoidosis. Current guidelines recommend evaluating for cardiac sarcoidosis (CS) in patients below 60 years with unexplained complete heart block (CHB).
OBJECTIVES: The aim of the study was to assess the proportion of patients with unexplained CHB who receive guideline-recommended testing for CS and to compare subsequent diagnosis rates with expected prevalence.
METHODS: We conducted a retrospective cohort study using TriNetX data, identifying patients aged 18 to 60 years with unexplained CHB requiring device placement over the past 5 years. We assessed the use of cardiac diagnostic tests-cardiac magnetic resonance imaging, positron emission tomography, chest computed tomography, and myocardial biopsy-and tracked CS diagnoses over 5 years.
RESULTS: Among 1,279 patients meeting criteria across 55 health care organizations, 75% were treated at academic centers. The mean age was 48 ± 11 years; 53% were male, and 73% were White. Over a median follow-up of 724 days (Q1-Q3: 0-1,117), advanced cardiac testing was performed in 256 patients (20.0%; 95% CI: 17.8%-22.2%). Specific test utilization included cardiac magnetic resonance imaging in 131 patients (10.2%; 95% CI: 8.6%-11.9%), chest computed tomography in 141 (11.0%; 95% CI: 9.3%-12.7%), cardiac positron emission tomography in ≤10 (0.7%; 95% CI: 0.3%-1.3%), and myocardial biopsy in ≤10 (0.7%; 95% CI: 0.3%-1.3%). Fewer than 10 patients (<1%; 95% CI: 0.3%-1.3%) were diagnosed with CS, far below the expected prevalence of 19% to 34%.
CONCLUSIONS: Despite guideline recommendations, diagnostic testing for CS in younger patients with unexplained CHB remains low. This gap likely contributes to significant underdiagnosis and highlights the need for improved adherence to evaluation protocols.
OBJECTIVES: The aim of the study was to assess the proportion of patients with unexplained CHB who receive guideline-recommended testing for CS and to compare subsequent diagnosis rates with expected prevalence.
METHODS: We conducted a retrospective cohort study using TriNetX data, identifying patients aged 18 to 60 years with unexplained CHB requiring device placement over the past 5 years. We assessed the use of cardiac diagnostic tests-cardiac magnetic resonance imaging, positron emission tomography, chest computed tomography, and myocardial biopsy-and tracked CS diagnoses over 5 years.
RESULTS: Among 1,279 patients meeting criteria across 55 health care organizations, 75% were treated at academic centers. The mean age was 48 ± 11 years; 53% were male, and 73% were White. Over a median follow-up of 724 days (Q1-Q3: 0-1,117), advanced cardiac testing was performed in 256 patients (20.0%; 95% CI: 17.8%-22.2%). Specific test utilization included cardiac magnetic resonance imaging in 131 patients (10.2%; 95% CI: 8.6%-11.9%), chest computed tomography in 141 (11.0%; 95% CI: 9.3%-12.7%), cardiac positron emission tomography in ≤10 (0.7%; 95% CI: 0.3%-1.3%), and myocardial biopsy in ≤10 (0.7%; 95% CI: 0.3%-1.3%). Fewer than 10 patients (<1%; 95% CI: 0.3%-1.3%) were diagnosed with CS, far below the expected prevalence of 19% to 34%.
CONCLUSIONS: Despite guideline recommendations, diagnostic testing for CS in younger patients with unexplained CHB remains low. This gap likely contributes to significant underdiagnosis and highlights the need for improved adherence to evaluation protocols.